MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute
graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell
transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The
most common symptoms ...
Age: 18 years - 66+
Gender: All
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with
sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease
(ACHD) patients by investigating the prescription patterns, safety, tolerability, and
potential b...
Age: 18 years - 66+
Gender: All
Human Milk Research Study
What is the purpose of the study?
The maternal RSV vaccine was licensed in 2023 for prevention of RSV-associated lower respiratory tract disease in infants up to six months of age. Maternal immunization protects infants via antibodies transferred in utero. Additional be...
Age: 18 - 50 years
Gender: Female
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
This will be a pilot multi-arm clinical trial investigating the feasibility of 6 weeks of Lumbrokinase (LK) as an intervention in three clinical cohorts:
Long Covid (LC)
Post-treatment Lyme disease syndrome (PTLDS)
Myalgic encephalomyelitis/chronic fatigue syndrome (ME...
Age: 18 years - 66+
Gender: All
Multi-omics Study in Citrin Deficiency
Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by
several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin
deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and
dyslipidemia" ...
Age: 0 - 100 years
Gender: All
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Induction therapy approaches in recent years have evolved, now utilizing triple or
quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies,
proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients
achieve long...
Age: 70 years - 66+
Gender: All
EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive
Prenatal Test. The development of this investigational single-gene noninvasive prenatal
testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy
(SMA), Sic...
Age: 18 years - 66+
Gender: All
Enfortumab Vedotin Plus Pembrolizumab with Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus
pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and
cystoscopy with TURBT of any visible tumor and/or resection site plus random biopsies
using a r...
Age: 18 years - 66+
Gender: All
Evaluation of the Abbott i-STAT TBI Biomarker Test
According to the Centers for Disease Control and Prevention, approximately 200,000
hospitalizations occurred in 2020 related to Traumatic Brain Injury (TBI), which does not
include many TBIs treated only in emergency departments, urgent care, primary care, or
that ar...
Age: 18 years - 66+
Gender: All
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
The goal of this observational study is to understand how genomic and epigenetic factors
contribute to resistance against chemo-immunotherapy in adults diagnosed with
extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine
carcinoma (...
Age: 18 - 85 years
Gender: All
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the
accuracy of an investigational artificial intelligence (AI) Software as a Medical Device
(SaMD) designed to compute ejection fraction (EF) severity categories based on the
America...
Age: 18 years - 66+
Gender: All
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of
NEU-411 in men and women aged 50-80 years with early Parkinson's Disease (PD) who have
predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for
short) ...
Age: 50 - 80 years
Gender: All
Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management
The Icahn School of Medicine at Mount Sinai will conduct a randomized controlled trial of
a self-management support intervention for predominantly minoritized and low-income
adults with chronic obstructive pulmonary disease (COPD). The trial will focus on
comprehensi...
Age: 40 years - 66+
Gender: All
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the
treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains
a high unmet need for effective therapies for participants who have recurrent disease and
dis...
Age: 18 years - 66+
Gender: All
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus
Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in
Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell
Transplantation
Age: 18 years - 66+
Gender: All
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled,
parallel-group study, followed by an OLE, is designed to evaluate the safety,
tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD.
LRRK2-PD is defined as ...
Age: 30 years - 66+
Gender: All
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3
Investigate the long-term impact of amount and duration of Tailored Lighting Intervention
(TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and
behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study,
the re...
Age: 55 years - 66+
Gender: All
Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)
Recent retrospective studies have demonstrated differences between pulse oximeter values (SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or Hispanic. These retrospective studies have limitations because self-reported race is likely...
Age: Birth - 18 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
The Mount Sinai IBD Biobank and Data Repository
Approximately 1.4 million people in the United States have been affected by inflammatory bowel disease (IBD), and the number is growing. The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai is conducting research to understand t...
Age: 0 - 100 years
Gender: All